original ) (raw )Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance
Rodrigo Goncalves
View PDFchevron_right
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Etienne Brain
Breast Cancer Research and Treatment, 2012
View PDFchevron_right
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Sherri Davies
2009
View PDFchevron_right
Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
Elham Jafari
Iranian journal of pathology, 2018
View PDFchevron_right
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up
Mario Airoldi
Breast Cancer Research and Treatment, 2016
View PDFchevron_right
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
F. Maffini
JNCI Journal of the National Cancer Institute, 2008
View PDFchevron_right
The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer
N. Pathmanathan
Journal of Clinical Pathology, 2014
View PDFchevron_right
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer
Per Malmström
SpringerPlus, 2013
View PDFchevron_right
Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy
Cynthia Villarreal-Garza
The oncologist, 2018
View PDFchevron_right
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
V. Möbus
Annals of Oncology, 2014
View PDFchevron_right
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
Gunter Von Minckwitz
Breast Cancer Research, 2008
View PDFchevron_right
Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer
B. Killelea , Donald Lannin , Michael Digiovanna
Laboratory Investigation, 2013
View PDFchevron_right
Trends in Adjuvant Chemotherapy Use in Endocrine-Sensitive, HER-2 Negative Breast Cancer, With 1 to 3 Positive Nodes: A Single-Centre Study
Archives Breast Cancer
Archives of Breast Cancer, 2021
View PDFchevron_right
Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
Neha Dahiya , Rodrigo Goncalves
View PDFchevron_right
Benefits of Neoadjuvant Chemotherapy for Luminal Breast Cancer with Respect to Tumor Response
Ali Aktekin
Journal of Oncological Sciences, 2021
View PDFchevron_right
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole
Eugenio Maiorano
Journal of Clinical Oncology, 2008
View PDFchevron_right
The Clinical Impact of Neoadjuvant Endocrine Treatment On Luminal-Like Breast Cancers and Its Prognostic Significance: Results From a Single-institution Prospective Cohort Study
José I. Sánchez Méndez
Research Square (Research Square), 2022
View PDFchevron_right
Assessment of the Prognostic Role of Ki-67 and Its Optimal Cutoff Value in Early Breast Cancer: A Retrospective Analysis
Wael Makar
Research in Oncology
View PDFchevron_right
Relationship About KI67 and Chemotherapy Regimens About Progression Free Survival in Triple Negative Breast Cancer
Journal of Medical Research and Surgery Indexing
Journal of Medical Research and Surgery, 2021
View PDFchevron_right
Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
Susana Ramalho
Revista Brasileira de Ginecologia e Obstetrícia, 2019
View PDFchevron_right
Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer
Caron Ory
Journal of Oncology Practice
View PDFchevron_right
Ki67 and breast cancer mortality in women with invasive breast cancer
Jake Probert
JNCI Cancer Spectrum
View PDFchevron_right
Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model
Kamyar Kahnamoui , Valerie Francescutti , Richard Tozer
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma
Veronique Dieras , Virginie Fourchotte
PLoS ONE, 2013
View PDFchevron_right
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
R. D'Amico
Annals of Oncology, 2009
View PDFchevron_right
Roles of Ki67 in Breast Cancer - Important for Management?
Pathmanathan Rajadurai
Asian Pacific Journal of Cancer Prevention, 2016
View PDFchevron_right
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Robin L Jones
Breast Cancer Research and Treatment, 2009
View PDFchevron_right
Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
Janina Kulka
Diagnostic Pathology, 2017
View PDFchevron_right
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Giuseppe Viale
Breast Diseases: A Year Book Quarterly, 2012
View PDFchevron_right